Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Androgeendeprivatie plus radiotherapie als salvagebehandeling na radicale prostatectomie
jan 2020 | Uro-oncologie